T1	Intervention 1064 1162	Patients, investigators, study monitors, and the sponsor staff were masked to treatment allocation
T2	Intervention 1164 1199	Response was assessed every 8 weeks
T3	Intervention 764 1062	assigned (2:1) with a central randomisation schedule to receive intravenous ganitumab 12 mg per kg bodyweight or placebo in combination with open-label intramuscular fulvestrant (500 mg on day 1, then 250 mg on days 15, 29, and every 28 days) or oral exemestane (25 mg once daily) on a 28-day cycle
